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Observational study on the palatability and 
tolerability of oral prednisolone and oral 
dexamethasone in children in Saudi Arabia and 
the UK
Fahad Aljebab,1 Mofadhi Alanazi,2 Imti Choonara,1 Sharon Conroy1
AbstrAct
background Short-course oral corticosteroids are 
routinely used to treat acute asthma and croup. We 
evaluated their tolerability and palatability in Saudi 
Arabian (SA) and UK children.
Methods Prospective observational/interview study 
(3 months in each country). Palatability was evaluated 
using a 5-point facial Hedonicscale and tolerability by 
direct questioning of patient/parents.
results In SA, of 122 patients (2–10 years) 
recruited, 52 received prednisolone base tablets, 37 
prednisolone sodium phosphate syrup and 33 received 
dexamethasone elixir. In the UK, of 133 patients 
(2–16 years), 38 received prednisolone base tablets 
(mainly crushed and dispersed), 42 prednisolone 
sodium phosphate soluble tablets and 53 received 
dexamethasone sodium phosphate oral solution. In 
both countries, dexamethasone had the highest 
palatability scores (SA mean: 1.97; UK mean: 3) and 
prednisolone base tablets had the lowest (SA mean: 
1.12; UK mean: 1.39). Palatability scores improved for 
all formulations of prednisolone with each subsequent 
daily dose. In SA, prednisolone base tablets were 
associated with more nausea (24vs7 patients) and 
vomiting (5vs0 patients) than sodium phosphate syrup 
(p=0.008 and p=0.073, respectively). In the UK, vomiting 
occurred more frequently with prednisolone base (8 
patients) than sodium phosphate soluble tablets (2 
patients) (p=0.041). In both centres, dexamethasone 
was associated with less side effects. Vomiting (1vs0 
patients), nausea (7vs3 patients) and abdominal pain 
(10vs8 patients) occurred more with dexamethasone 
sodium phosphate solution than dexamethasone elixir.
conclusions Dexamethasone sodium phosphate 
solution was the most palatable preparation. 
Prednisolone base tablets were rated least palatable and 
were least well tolerated. Palatability scores improved 
with each dose taken.
IntrODuctIOn
Corticosteroids are widely used to treat a variety 
of medical conditions. The palatability and toler-
ability of medication is an important factor influ-
encing adherence to medication particularly in 
children. The European Medicines Agency advises 
that medicinal products should be made in formu-
lations with an acceptable taste for children.1 Oral 
corticosteroids often have a bitter taste and are also 
associated with a wide variety of adverse effects.2 
Tolerability relates to several factors including taste 
and adverse symptoms such as vomiting, nausea 
and abdominal pain that can affect quality of life 
and willingness to continue treatment.3
A recent systematic review found that gastroin-
testinal disorders including vomiting, nausea and 
abdominal pain were the most common side effects 
of oral corticosteroids given in short courses.4 In 
the studies where formulation was discussed, pred-
nisolone sodium phosphate solution had a lower 
risk of vomiting than both prednisolone (base) 
solution and oral dexamethasone.4 Only one study 
compared both the palatability and tolerability of 
oral prednisolone and dexamethasone. This study 
found that dexamethasone was more likely to cause 
vomiting than prednisolone.5
We describe a prospective observational study in 
the paediatric wards of Gurayat General Hospital 
(GGH) in Saudi Arabia (SA) and Derbyshire Chil-
dren's Hospital in the UK to evaluate and compare 
the tolerability and palatability of routinely used 
preparations of oral prednisolone for patients with 
asthma and oral dexamethasone for patients with 
croup.
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Drug therapy
What is already known on this topic?
 ► Oral prednisolone and dexamethasone are 
widely used in children to treat conditions such 
as asthma and croup.
 ► The taste of prednisolone in particular is an 
issue which may affect adherence to treatment 
in children.
What this study adds?
 ► Dexamethasone was rated as more palatable 
than prednisolone in two different countries.
 ► Prednisolone sodium phosphate seems to 
cause significantly less nausea and vomiting 
than prednisolone base and is rated more 
palatable.
 ► Experienced patients gave better taste scores 
for all formulations compared with naive 
patients.
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MethODs
The study was conducted in the children's emergency depart-
ment (ED) of the two hospitals. Children suffering from asthma 
or croup, prescribed oral prednisolone or dexamethasone and 
able to understand the study’s palatability scale and communi-
cate their response were approached for consent. The drugs and 
products administered were in accordance with standard prac-
tice in each department. Choice of product and routine care of 
the patients were unaffected by the study.
In SA, patients were treated with prednisolone base 5 mg 
tablets (Gupisone, Julphar, UAE), prednisolone sodium 
phosphate 15 mg/5 mL syrup (Predo, Jazeera Pharmaceu-
tical Industries, SA) and dexamethasone 0.5 mg/5 mL elixir 
(Decadron, Algorithm Pharmaceutical Manufacturers, 
Lebanon). The study was conducted for 3 months between 1 
February and 30 April 2015 in GGH. It included only chil-
dren  ≤12  years  of  age  as  paediatric  admissions  in  SA  are 
limited to this age.
Figure 1 Data collection form.
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In the UK, children (2–18 years) were treated with predniso-
lone base 5 mg tablets (prednisolone, Actavis UK, UK), prednis-
olone sodium phosphate 5 mg soluble tablets (soluble prednis-
olone, Amdipharm UK, UK) and dexamethasone sodium phos-
phate 2 mg/5 mL solution (dexamethasone, Focus Pharmaceuti-
cals, UK). The study was conducted in the children’s accident & 
emergency (A&E) department and hospital wards, for 3 months 
between 15 September and 21 December 2015.
We used a 5-point facial Hedonic Scale to assess palatability in 
both countries, as used previously in studies comparing the taste 
of analgesic and corticosteroid preparations in children.6 7 The 
scale was explained to the patient and parent by the researcher 
who were then asked to rate the palatability of the medication 
within 10 min of taking the drug where possible, by pointing to 
the appropriate face. To evaluate taste in younger patients who 
were unable to self-report, parents were asked to help in inter-
preting what their child thought of the taste of the medication.
Tolerability (nausea, vomiting and abdominal pain) as 
reported by the parent/patients in response to direct questions 
was documented 30–60 min after each drug administration. To 
evaluate nausea in younger patients unable to self-report this 
symptom, their parents were asked if they had observed any 
change in their child’s well-being which suggested them to be 
experiencing nausea including dizziness, lethargy or being cold 
and clammy.
Palatability and tolerability ratings were obtained from 
patients after each dose of medication until the course ended. 
The researcher contacted the parents by telephone if the patient 
had been discharged, alternatively parents were given the option 
to complete the data collection form themselves and return it by 
post using a prepaid envelope.
The data collection form (DCF) used for each patient was a 
modification of questions used in two previous studies of accept-
ability and/or side effects in children receiving short course pred-
nisolone for the treatment of acute asthma8 9 (figure 1).
Percentages and χ2 testing were used for categorical vari-
ables to compare between tastes of different dosage forms and 
the tolerability of each drug. Categorical data were compared 
table 1 Demographics of recruited children
total number of patients
(n=255)
sA uK
Prednisolone base 
tablet
(n=52)
Prednisolone sodium 
phosphate syrup
(n=37)
Dexamethasone elixir
(n=33)
Prednisolone base 
tablet
(n=38)
Prednisolone sodium 
phosphate soluble 
tablet
(n=42)
Dexamethasone
sodium phosphate 
solution
(n=53)
Age (years) Median 4.5 4 3.5 5 4 3
Range (2–10) (2–10) (2–5.5) (2.4–16) (2–14) (2–10)
IQR 3–6 3–5 3–4.75 3.38–7.5 3–7 2.5–5
Gender Male (%) 34 (65.4) 18 (48.6) 18 (54.5) 22 (58) 29 (69) 28 (53)
Female (%) 18 (34.6) 19 (51.4) 15 (45.5) 16 (42) 13 (31) 25 (47)
Weight (kg) Median 18 15 14 20 17.8 17
Range (10–35) (10–30) (10–21) (11.5–77) (10.3–80) (12–48.7)
Dose (mg/kg/day) Median 2 2 0.3 1.2 1.1 0.2
Range (1.5–2) 2 (0.2–0.4) (1.2–2) (0.4–2) (0.1–0.6)
Dose duration (day) Median 3 3 1 3 3 1
Range (1–5) (3–5) 1 (1–5) (1–5) 1
Received oral steroids 
before
Yes 24 20 0 29 27 18
No 28 17 33 9 15 35
SA, Saudi Arabia.
table 2 Palatability of oral corticosteroids in SA
total number of patients
(n=122) no
taste of medication
Mean of 
taste score 
(1–5)* sD 95% cI for mean p-Value
Dislike very 
much (%)
Dislike a little 
(%)
not sure or 
neutral (%)
Day 1 n=122 Prednisolone base 52 46 (89) 6 (11) 0 1.12 0.32 (1.03 to 1.21) <0.0001†‡ 
Prednisolone Sodium 
Phosphate
37 18 (49) 15 (40) 4 (11) 1.62 0.68 (1.39 to 1.85)
Dexamethasone 33 9 (27) 16 (49) 8 (24) 1.97 0.73 (1.71 to 2.23)
Day 2 n=82 Prednisolone base 45 29 (64) 13 (29) 3 (7) 1.42 0.62 (1.24 to 1.61) <0.0001*
Prednisolone sodium 
phosphate
37 4 (11) 25 (68) 8 (21) 2.11 0.57 (1.92 to 2.30)
Day 3 n=74 Prednisolone base 42 17 (40) 22 (53) 3 (7) 1.67 0.61 (1.48 to 1.86) <0.0001*
Prednisolone sodium 
phosphate
32 1 (3) 18 (56) 13 (41) 2.38 0.55 (2.18 to 2.57)
Day 4 n=11 Prednisolone base 10 1 (10) 7 (70) 2 (20) 2.1 0.57 (1.69 to 2.51) 0.364±
Prednisolone 
sodium phosphate
1 0 0 1 (100) 3 – –
Day 5 n=5 Prednisolone base 5 0 3 (60) 2 (40) 2.4 0.54 – –
*1=dislike very much, 2=dislike a little, 3=not sure, 4=like a little, 5=like very much.
†Significant results.
‡Fisher’s exact test. 
SA, Saudi Arabia.
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using the χ2 or Fisher’s exact test where appropriate. The McNe-
mar-Bowker test was used to compare among the same group of 
patients how the taste score changed between different days. A 
significance level of p<0.05 was accepted as significant for all 
the tests.
In SA, ethical approval (Ref: 620/13/54) was obtained from 
the hospital Quality and Patient Safety Committee (QPSC) on 
23 December 2014. In the UK, ethical approval (REC Ref: 15/
EM/0057) was obtained from East Midlands—Derby Research 
Ethics Committee on 19 March 2015.
results
Overview
In SA, 141 children were approached for the study. Nineteen 
children were not recruited: 11 because the parents refused 
to take part and 8 children were missed for observation 
(see online supplementary figure 1). One hundred and twen-
ty-two children were enrolled to the study (table 1). Most of 
them were with asthma (89) aged 2–10 years, and the others had 
croup (33) aged 2–5.5 years. The patients with asthma received 
two formulations of prednisolone (52 received prednisolone 
base soluble tablets and 37 received prednisolone sodium phos-
phate syrup). The croup patients all received oral dexametha-
sone elixir. Prednisolone base tablets were crushed and dispersed 
in water in all cases. Most patients were aged between 2 and 5 
years old. The dose between prednisolone groups was almost 
the same. Around half of the patients in the prednisolone groups 
had received oral steroids in previous disease episodes, while in 
the dexamethasone group no patients had oral steroids before.
In the UK, a total of 147 children were approached. Four-
teen children were not recruited: 6 because the parents refused 
to take part and 8 children were missed for observation 
(see online supplementary figure 2). One hundred and thir-
ty-three children were enrolled to the study (table 1). Most of 
them were with asthma (80) aged 2–16 years and the others had 
croup (53) aged 2–10 years. The patients with asthma received 
two formulations of prednisolone (38 received prednisolone base 
tablets and 42 received prednisolone sodium phosphate soluble 
tablets), and all patients with croup received oral dexametha-
sone sodium phosphate solution. Crushed prednisolone base 
tablets and prednisolone sodium phosphate soluble tablets were 
dispersed/dissolved in water and a few patients followed admin-
istration by a drink of blackcurrant juice if the patient chose to 
when offered this by a nurse. Only five patients received solid 
prednisolone base tablets. Most patients were aged between 2 
and 5 years old in all corticosteroid groups. The dose between 
prednisolone groups was almost the same. Most patients in the 
prednisolone groups had received oral steroids previously, while 
in the dexamethasone group most patients had not received oral 
steroids before.
Palatability
In SA, the majority of the children on the first day disliked the 
taste of the medicines (100% of prednisolone base tablet group, 
89% of prednisolone sodium phosphate group and 76% of 
dexamethasone group) and no patients stated that they liked the 
taste on any day (table 2). Prednisolone base was disliked the 
most (89%), and dexamethasone was disliked the least (27%) 
(p<0.0001). Both prednisolone base tablets and prednisolone 
sodium phosphate syrup were rated significantly more palatable 
day by day (see online supplementary table 1).
The children who had received oral corticosteroids before 
(experienced patients) reported different palatability scores 
compared with the children who received the medicine for the 
first time (naive patients). These differences in taste scores were 
statistically significant on the first 3 days (figure 2).
In the UK, the majority of the children on the first day disliked 
the taste of the medicines (90% of prednisolone base tablet 
group, 62% of prednisolone sodium phosphate group and 34% 
of dexamethasone group) (table 3). On day 1, most patients 
that received prednisolone base (77%) disliked the medication 
very much as did 36% of the prednisolone sodium phosphate 
group. Only 6% of patients disliked dexamethasone very much 
(p<0.0001). Both prednisolone base tablets and prednisolone 
sodium phosphate soluble tablets were rated significantly more 
palatable day by day (see online supplementary table 1).
The children who had received oral corticosteroids before 
(experienced patients) reported different palatability scores 
compared with the children receiving the medicine for the first 
time (naive patients). These differences in taste scores were 
Figure 2 Mean taste scores of prednisolone base and prednisolone sodium phosphate according to drug history in SA and in the UK. Pred. Base, 
prednisolone base; Pred. Na3PO4, prednisolone sodium phosphate; E, experienced patients; N, naive patients; SA, Saudi Arabia.
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statistically significant on day 3 only (figure 2). Most treat-
ment naive croup patients disliked the taste a little (40%) or 
were neutral (40%), while 33.3% of experienced patients were 
neutral, 33.3% liked the taste a little and 17% liked the taste very 
much. The differences were statistically significant (p=0.021).
tolerability
In SA, five patients in the prednisolone base group experi-
enced vomiting, while no patients experienced vomiting in the 
prednisolone sodium phosphate group (p=0.073). Nausea was 
reported among almost half of the patients taking the prednis-
olone base formulation (24 patients). This was significantly 
more frequent than with the prednisolone sodium phosphate 
formulation (OR=3.67; 95% CI 1.26 to 11.58, p=0.008). 
Abdominal pain, however, was reported more frequently in 
patients taking the prednisolone sodium phosphate formu-
lation (n=13) than in patients taking the prednisolone base 
formulation (n=8) (OR=2.9; 95% CI 1.1 to 8.1, p=0.031). 
The patients who received dexamethasone experienced nausea 
and abdominal pain at rates of 9% and 24%, respectively, of 
the total 33 patients, but no patients experienced vomiting. 
Other side effects were also reported. Behavioural change and 
sleep disturbance were the most common side effects. They 
occurred much more frequently with prednisolone base tablets 
than prednisolone sodium phosphate syrup, behavioural 
change (9 vs 2) and sleep disturbance (9 vs 3). The differences 
were, however, not significant (p=0.11 and p=0.34, respec-
tively).
In the UK, eight patients in the prednisolone base group and 
two patients in the prednisolone sodium phosphate group expe-
rienced vomiting (p=0.041). Nausea was significantly more 
frequent being reported by almost half the patients taking the 
prednisolone base formulation (17) compared with a third of 
patients taking prednisolone sodium phosphate (11) (OR=2.3; 
95% CI 0.8 to 6.5, p=0.103). Abdominal pain was reported more 
frequently in patients taking the prednisolone base formulation 
(n=10) than with the prednisolone sodium phosphate formula-
tion (n=7) (OR=1.8; 95% CI 0.5 to 6.3, p=0.413). The patients 
who received dexamethasone experienced vomiting, nausea and 
abdominal pain at rates of 1.9%, 13.2% and 18.9%, respectively, 
among the total number of patients (53 patients). Other side 
effects were also reported. Behavioural change and sleep distur-
bance were the most common side effects. They occurred more 
frequently with prednisolone base tablets than prednisolone 
sodium phosphate soluble tablets, behavioural change (11 vs 9) 
and sleep disturbance (6 vs 2). The differences were, however, 
not significant (p=0.45 and p=0.14, respectively).
DIscussIOn
Taste affects the acceptability of medication and may affect 
adherence. In these two countries, children consistently reported 
that dexamethasone tasted better than prednisolone; predniso-
lone base tasted the worst and prednisolone sodium phosphate 
was more palatable than prednisolone base. Others have also 
demonstrated differences in the palatability of different formu-
lations.10 11
Nausea and vomiting were more frequent with prednisolone 
base tablets in both countries. Prednisolone sodium phosphate 
syrup resulted in more abdominal pain in the SA children. 
Others have demonstrated increased vomiting with prednisolone 
base tablets.10 This variation of reported side effects shows that 
the formulation is important. Most children in both countries 
required the prednisolone base tablets to be dispersed in water t
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prior to administration as they could not swallow whole tablets. 
This may have reduced the tolerability.
Children in both countries who received dexamethasone were 
more likely to experience abdominal pain rather than nausea and 
vomiting. A previous meta-analysis also found that vomiting was 
more frequent with prednisolone compared with dexametha-
sone.4
If improved taste and less side effects were the only deciding 
factors, prednisolone sodium phosphate would appear to be 
the best choice for asthmatic children of the commonly used 
medications, but other factors also need to be considered. Oral 
dexamethasone has been shown to be an effective alternative 
to oral prednisolone in the treatment of acute asthma in chil-
dren.12 Keeney et al suggested that 2 days of oral dexametha-
sone is similarly effective to 5 days of oral prednisolone with 
evidence that dexamethasone might be better tolerated and 
require shorter duration of therapy.13 Since dexamethasone was 
the overall most palatable and best-tolerated preparation when 
given as a single dose for croup, this may suggest that it would 
be a useful alternative in the treatment of children with acute 
asthma episodes.
Another factor which must also be considered is the cost of 
the medication, with prednisolone sodium phosphate tablets 
costing 60 times more than prednisolone base tablets in the UK 
(see online supplementary table 2).14 As a result, many centres 
in the UK have moved to using prednisolone base tablets despite 
patients finding them less palatable and tolerable. Annual cost 
savings of up to £44 000 in a single UK hospital have been 
predicted.15
Taste ratings improved throughout the duration of the treat-
ment. In addition, children who had received oral corticoste-
roids before (experienced patients) reported significantly higher 
(more favourable) palatability scores than children who received 
the medicine for the first time (naive patients) in both countries 
studied. Research suggests that the physiology and neurobio-
logical mechanisms underlying the taste function mean that the 
impression of taste changes with time and experience and leads 
to adaptation of taste perception.16 The experienced patient who 
is familiar with the medication taste may therefore have adapted 
and started to accept it. This may also explain our findings that 
the taste ratings of all medications improved in both countries 
day by day. It is also possible that as treatment becomes effective 
and children start to feel better, they become more cooperative 
and tolerant. No other studies identified, however, have made 
this observation of increased tolerability with time or with expe-
rience for these drugs.
In conclusion, dexamethasone was rated more palatable than 
prednisolone. For patients with asthma, prednisolone base tablets 
were rated the least palatable preparation and were also the least 
well tolerated. Prednisolone sodium phosphate was associated 
with a significantly lower incidence of nausea and vomiting and 
better taste score, compared with prednisolone base. Best practice 
suggests that prednisolone sodium phosphate or dexamethasone 
should be used.
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